Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2021 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Return on Capital Employed of 19.63% in Q1 2026, down 821.63% quarter-over-quarter from 2.13% in Q4 2025, and down 1903.0% on a YoY basis from 1.09% in Q1 2025.
Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 19.63% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1903.0% year-over-year to 19.63%; the TTM figure through Mar 2026 stood at 19.63% (down 1903.0% YoY), while the FY2025 annual figure was 2.19%, up 3566.0% from the prior year.
- Return on Capital Employed was 19.63% for Q1 2026 at Monte Rosa Therapeutics, down from 2.13% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4.47% in Q2 2025 to a low of 61.95% in Q4 2023.
- Historically, Return on Capital Employed has averaged 31.48% across 5 years, with a median of 34.64% in 2022.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed sank 2764 bps in 2023, then soared 5843 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 34.64% in 2022, then plunged by 79 bps to 61.95% in 2023, then jumped by 40 bps to 36.88% in 2024, then soared by 94 bps to 2.13% in 2025, then tumbled by 822 bps to 19.63% in 2026.
- The last three Return on Capital Employed figures came in at 19.63% (Q1 2026), 2.13% (Q4 2025), and 2.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -19.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63% |
| Dec 31, 2025 | -2.13% |
| Sep 30, 2025 | 2.44% |
| Jun 30, 2025 | 4.47% |
| Mar 31, 2025 | -0.60% |
| Dec 31, 2024 | -36.88% |
| Sep 30, 2024 | -44.79% |
| Jun 30, 2024 | -52.99% |
| Mar 31, 2024 | -59.03% |
| Dec 31, 2023 | -61.95% |
| Sep 30, 2023 | -58.06% |
| Jun 30, 2023 | -48.17% |
| Mar 31, 2023 | -40.09% |
| Dec 31, 2022 | -34.64% |
| Sep 30, 2022 | -30.42% |
| Jun 30, 2022 | -27.82% |
| Mar 31, 2022 | -24.93% |
| Dec 31, 2021 | -20.33% |
| Sep 30, 2021 | -16.89% |